Erectile Dysfunction Pipeline Review, H1 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 22, 2019--
The “Erectile Dysfunction - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Erectile Dysfunction - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 2, 5, 7, 10, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.
Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
- The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)
- Adamis Pharmaceuticals Corp
- Aquestive Therapeutics Inc
- Astellas Pharma Inc
- Biozeus Pharmaceutical SA
- Can-Fite BioPharma Ltd
- Cure Pharmaceutical Inc
- Fabre-Kramer Pharmaceuticals Inc
- Futura Medical Plc
- Humanetics Corp
- Karessa Pharma Holding AB
- Mezzion Pharma Co Ltd
- Mitsubishi Tanabe Pharma Corp
- NAL Pharmaceuticals Ltd
- Pharmicell Co Ltd
- SK Chemicals Co Ltd
- Suda Pharmaceuticals Ltd
- XuanZhu Pharma Co Ltd
- Yangtze River Pharmaceutical Group
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/73b742
View source version on businesswire.com:https://www.businesswire.com/news/home/20190522005679/en/
Laura Wood, Senior Press Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Sexual and Reproductive Health Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/22/2019 12:47 PM/DISC: 05/22/2019 12:47 PM